Integrating Single-Cell Transcriptomics and Machine Learning to Define an ac4C Gene Signature in Lung Adenocarcinoma.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-08-01 DOI:10.1111/1759-7714.70140

Yuan Wang, Wei Su, Guangyao Zhou, Yijie Wang, Chunnuan Wu, Pengpeng Zhang, Lianmin Zhang

{"title":"Integrating Single-Cell Transcriptomics and Machine Learning to Define an ac4C Gene Signature in Lung Adenocarcinoma.","authors":"Yuan Wang, Wei Su, Guangyao Zhou, Yijie Wang, Chunnuan Wu, Pengpeng Zhang, Lianmin Zhang","doi":"10.1111/1759-7714.70140","DOIUrl":null,"url":null,"abstract":"Introduction: Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, faces challenges such as drug resistance and tumor heterogeneity. N4-acetylcytidine (ac4C) is an important RNA modification involved in cancer progression, but its role in lung adenocarcinoma remains unclear.Methods: This study analyzed transcriptomic and single-cell RNA sequencing data from public databases to investigate the expression and clinical significance of ac4C-related genes in lung adenocarcinoma. Ten machine learning algorithms were applied to develop and validate an ac4C-related gene signature (ARGSig) for prognosis prediction across multiple independent cohorts.Results: Cells with high ac4C activity showed increased intercellular communication and activation of tumor-associated pathways. The ARGSig model effectively stratified patients by survival outcomes and predicted sensitivity to immune checkpoint inhibitors and chemotherapy agents.Conclusion: ac4C modification and its related genes play a critical role in lung adenocarcinoma development. The ARGSig model provides a promising molecular tool for prognosis evaluation and personalized treatment guidance in lung adenocarcinoma patients.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 15","pages":"e70140"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326626/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.70140","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, faces challenges such as drug resistance and tumor heterogeneity. N4-acetylcytidine (ac4C) is an important RNA modification involved in cancer progression, but its role in lung adenocarcinoma remains unclear.

Methods: This study analyzed transcriptomic and single-cell RNA sequencing data from public databases to investigate the expression and clinical significance of ac4C-related genes in lung adenocarcinoma. Ten machine learning algorithms were applied to develop and validate an ac4C-related gene signature (ARGSig) for prognosis prediction across multiple independent cohorts.

Results: Cells with high ac4C activity showed increased intercellular communication and activation of tumor-associated pathways. The ARGSig model effectively stratified patients by survival outcomes and predicted sensitivity to immune checkpoint inhibitors and chemotherapy agents.

Conclusion: ac4C modification and its related genes play a critical role in lung adenocarcinoma development. The ARGSig model provides a promising molecular tool for prognosis evaluation and personalized treatment guidance in lung adenocarcinoma patients.

查看原文本刊更多论文

整合单细胞转录组学和机器学习来定义肺腺癌中的ac4C基因标记。

肺腺癌是非小细胞肺癌中最常见的亚型，面临着耐药和肿瘤异质性等挑战。n4 -乙酰胞苷（ac4C）是参与癌症进展的重要RNA修饰，但其在肺腺癌中的作用尚不清楚。方法：本研究通过分析公共数据库转录组学和单细胞RNA测序数据，探讨ac4c相关基因在肺腺癌中的表达及其临床意义。应用十种机器学习算法来开发和验证ac4c相关基因标记（ARGSig），用于跨多个独立队列的预后预测。结果：高ac4C活性的细胞细胞间通讯增加，肿瘤相关通路激活。ARGSig模型根据生存结果有效地对患者进行分层，并预测对免疫检查点抑制剂和化疗药物的敏感性。结论：ac4C修饰及其相关基因在肺腺癌的发生发展中起关键作用。ARGSig模型为肺腺癌患者的预后评估和个性化治疗指导提供了一个有前景的分子工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.